Combination Chemotherapy with the M-2 Protocol (BCNU, Cyclophosphamide, Vincristine, Melphalan, and Prednisone) for Chronic Lymphocytic Leukemia (Stages III and IV)
- 1 January 1985
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 42 (6) , 350-353
- https://doi.org/10.1159/000226062
Abstract
The M-2 protocol was administered every 5 weeks to 25 patients with stage IIIand IV chronic lymphocytic leukemia (CLL). Complete remission (CR; absence of all clinical and bone marrow evidence of leukemia including normal immune markers for monoclonal disease) and partial remission (PR; >50% decrease in organ enlargement and reduction of WBC count to below 15,000 × 106/1) were achieved in 20 and 48%, respectively. A median number of 24 cycles of therapy was required to produce a CR. The median duration of unmaintained remission was 12 months. All CR patients are still surviving. The median survival of the PR patients and the overall groups is 21 months. To improve the CR rate and survival in patients with advanced CLL, more effective methods of determining residual leukemic cells and different treatment strategies will be needed.Keywords
This publication has 11 references indexed in Scilit:
- COMBINATION CHEMOTHERAPY (M-2) PROTOCOL (BCNU, CYCLOPHOSPHAMIDE, VINCRISTINE, MELPHALAN, AND PREDNISONE) FOR WALDENSTROMS MACROGLOBULINEMIA - PRELIMINARY-REPORT1982
- Detection of Small Numbers of Monoclonal B Lymphocytes in the Blood of Patients with LymphomaNew England Journal of Medicine, 1979
- In vitro leukocyte thymidine uptake and prognosis in chronic lymphocytic leukemiaThe American Journal of Medicine, 1979
- Clinical Classification and Survival in Chronic Lymphocytic LeukemiaTumori Journal, 1979
- Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocolThe American Journal of Medicine, 1977
- A clinical staging system for chronic lymphocytic leukemia.Prognostic significanceCancer, 1977
- Chronic lymphocytic leukemia: Correlation of clinical course and therapeutic response with in vitro testing and morphology of lymphocytesAmerican Journal of Hematology, 1977
- Mouse Red-Cell Rosettes in B-Lymphoproliferative DisordersBritish Journal of Haematology, 1976
- Factors influencing the duration of survival of patients with chronic lymphocytic leukemiaThe American Journal of Medicine, 1966
- Expectancy for Life in Chronic Lymphatic LeukemiaBlood, 1965